Module

Novel Therapies for Waldenstrom’s Macroglobulinemia

Source: Advances in the Treatment of Lymphoproliferative Malignancies: Promising Directions in Mantle Cell Lymphoma, Follicular Lymphoma, and Waldenstrom’s Macroglobulinemia

Novel Therapies for Waldenstrom’s Macroglobulinemia


CME Program Director: James O. Armitage, MD

Faculty:

  • Steven P. Treon, MD, MA, PhD

CME CREDIT INFORMATION

Release Date: 09/28/07

Expiration Date: 09/27/08


Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe recommended agents for the first-line treatment of Waldenström’s macroglobulinemia
  • Discuss the use of immunomodulatory drugs in the treatment of Waldenström’s macroglobulinemia
  • Identify targeted agents used to treat Waldenström’s macroglobulinemia

Topics covered include:

  • Introduction
  • Consensus Panel Recommendations
  • Nucleoside Analogues in WM
  • Immunomodulatory Drugs in WM
  • Mast Cell Interactions
  • Bortezomib Monotherapy in WM
  • Bortezomib, Dexamethasone, and Rituximab as Primary Treatment for WM
  • Alemtuzumab in WM
  • Imatinib in WM
  • Sildenafil in WM
  • Statins in WM
  • Future Directions in WM
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by University of Nebraska Medical Center, Center for Continuing Education and Clinical Care Options, LLC.

Educational grant provided by: